The Technical Analyst
Inhibikase Therapeutics, [IKT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Inhibikase Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.39% $2.13
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 13.80 mill |
| EPS: | -3.57 |
| P/E: | -0.600 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 6.48 mill |
| Avg Daily Volume: | 0.139 mill |
| RATING 2024-04-17 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.600 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.10x |
| Company: PE -0.600 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.397 (-81.38%) $-1.733 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.932 - 2.35 ( +/- 9.72%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Werner Milton H. | Buy | 45 000 | Stock Option (right to buy) |
| 2024-04-01 | Lees-rolfe Garth | Buy | 90 000 | Stock Option (right to buy) |
| 2024-04-01 | Lees-rolfe Garth | Sell | 5 834 | Stock Option (right to buy) |
| 2023-06-30 | Berman Dennis N | Buy | 6 667 | Stock Option (right to buy) |
| 2023-06-30 | Dion Gisele | Buy | 6 667 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 96.60 |
| Last 62 transactions |
| Buy: 1 923 769 | Sell: 2 120 717 |
Forecast:
16:00 - $2.14
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.14
Forecast 2: 16:00 - $2.14
Forecast 3: 16:00 - $2.14
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.13 (-1.39% ) |
| Volume | 0.0370 mill |
| Avg. Vol. | 0.139 mill |
| % of Avg. Vol | 26.55 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IKT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IKT
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Last 10 Buy Signals
| Date | Signal | @ |
|---|---|---|
| MPCC.OL | Apr 18 - 03:08 | NOK13.31 |
| TOM.OL | Apr 18 - 03:08 | NOK144.70 |
| SOFF.OL | Apr 18 - 03:08 | NOK41.32 |
| IDEX.OL | Apr 18 - 03:04 | NOK2.01 |
| SHLF.OL | Apr 18 - 03:05 | NOK19.62 |
| ENSU.OL | Apr 18 - 03:04 | 1.154 |
| SCHA.OL | Apr 18 - 03:03 | NOK307.60 |
| 2020.OL | Apr 18 - 03:02 | NOK151.50 |
| RTYUSD | Apr 18 - 03:07 | 1 969.70 |
| FLNG.OL | Apr 18 - 03:00 | NOK280.00 |
Latest Press Releases
2024-04-03 08:05:00 - Press Release
Inhibikase Therapeutics Announces Pre-ind Meeting With The Fda For Ikt-001pro In Pulmonary Arterial Hypertension
Meeting to discuss potential of ikt-001pro as a disease modifying treatment for pulmonary arterial hypertension meeting to discuss potential of ikt-001pro as a disease modifying treatment for pulmonary arterial hypertension
2024-03-27 16:15:00 - Press Release
Inhibikase Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Highlights Recent Activity
Company to host conference call on thursday, march 28, 2024 at 8:00 a.m. et company to host conference call on thursday, march 28, 2024 at 8:00 a.m. et
2024-03-07 08:30:00 - Press Release
Inhibikase Therapeutics To Provide Trial Update For Risvodetinib At The 2024 International Conference On Alzheimer's And Parkinson's Diseases And Related Neurological Disorders
Boston and atlanta, march 07, 2024 (globe newswire) -- inhibikase therapeutics, inc. (nasdaq: ikt) (“inhibikase” or “company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of parkinson's disease, parkinson's-related disorders and other diseases of the abelson tyrosine kinases, today announced that dr. milton werner, president and chief executive officer of inhibikase therapeutics, will present an update on the of the 201 trial evaluating risvodetinib (“risvo”) at the 2024 ad/pd meeting being held march 5-9, 2024 in lisbon, portugal.
2024-02-28 16:05:00 - Press Release
Inhibikase Therapeutics Announces Full Outcomes Of Its Pre-nda Meeting With The Fda For Ikt-001pro
Company to pursue eleven indications for ikt-001pro; all previously approved for treatment with imatinib mesylate company to pursue eleven indications for ikt-001pro; all previously approved for treatment with imatinib mesylate
2024-02-07 07:55:00 - Press Release
Inhibikase Therapeutics Announces Preliminary Outcomes Of Its Pre-nda Meeting With The Fda On The Pathway For Approval For Ikt-001pro In Blood And Gastrointestinal Cancers
- the company continues to progress the 201 trial evaluating risvodetinib in untreated parkinson's disease - - the company continues to progress the 201 trial evaluating risvodetinib in untreated parkinson's disease -
Latest News
2024-03-28 17:13:08 - Seeking Alpha
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript
2024-02-15 10:56:06 - Zacks Investment Research
Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now
Inhibikase Therapeutics, Inc. (IKT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2024-02-13 07:51:03 - Zacks Investment Research
New Strong Buy Stocks for February 13th
IKT, ETRN, ADMA, AFRM and ORC have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2023.
2024-02-08 11:01:08 - Zacks Investment Research
Best Momentum Stocks to Buy for February 8th
POST, IKT and ACMR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 8, 2023.
2024-02-08 07:41:04 - Zacks Investment Research
New Strong Buy Stocks for February 8th
IKT, POST, ASAN, ACMR and HENKY have been added to the Zacks Rank #1 (Strong Buy) List on February 8, 2023.
2024-02-06 10:01:35 - Zacks Investment Research
New Strong Buy Stocks for February 6th
EGO, SBSI, CCS, TCBX and IKT have been added to the Zacks Rank #1 (Strong Buy) List on February 6, 2023.
2024-01-31 07:05:15 - Zacks Investment Research
New Strong Buy Stocks for January 31st
ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
2024-01-26 11:01:06 - Zacks Investment Research
Best Momentum Stocks to Buy for January 26th
PCAR, IKT and PD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 26, 2023.
2024-01-26 07:26:04 - Zacks Investment Research
New Strong Buy Stocks for January 26th
IKT, EGO, MDB, PD and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.
2024-01-22 13:00:29 - Zacks Investment Research
Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?
Inhibikase Therapeutics, Inc. (IKT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.